How should I manage an allergic reaction to cyclobenzaprine (Flexeril)?

Management of Allergic Reaction to Cyclobenzaprine (Flexeril)

Immediately discontinue cyclobenzaprine and do not rechallenge the patient if a hypersensitivity reaction is suspected, as the FDA label explicitly contraindicates use in patients with hypersensitivity to any component of the product 1.

Acute Management Based on Reaction Severity

Severe Reactions (Anaphylaxis)

If the patient presents with anaphylaxis (difficulty breathing, facial/tongue swelling, hypotension, or multisystem involvement):

First-line treatment:

• Epinephrine IM immediately: 0.01 mg/kg (maximum 0.5 mg) in the anterolateral thigh using 1:1,000 solution, or use auto-injector (0.15 mg for <25 kg; 0.3 mg for ≥25 kg) 2
• Repeat every 5-15 minutes if symptoms persist or progress 2
• Transfer to emergency facility immediately 2

Adjunctive treatment (concurrent, not sequential):

• H1 antihistamine: Diphenhydramine 1-2 mg/kg (maximum 50 mg) IV or oral 2
• H2 antihistamine: Ranitidine 1-2 mg/kg (maximum 75-150 mg) 2
• Supplemental oxygen 2
• IV fluid bolus (10-20 mL/kg) if hypotensive or poor response to epinephrine 2
• Position patient recumbent with legs elevated 2
• Bronchodilator if bronchospasm: Albuterol 4-8 puffs (child) or 8 puffs (adult) via MDI 2
• Corticosteroids: Methylprednisolone 1 mg/kg (maximum 60-80 mg) IV or prednisone 1 mg/kg (maximum 60-80 mg) oral 2

Observation period:

• Minimum 4-6 hours in emergency facility after symptom resolution 3
• Longer observation or admission for severe/refractory reactions 3

Mild-to-Moderate Reactions (Urticaria, Rash, Pruritus)

For isolated cutaneous symptoms without systemic involvement:

• H1 antihistamine: Diphenhydramine 1-2 mg/kg (maximum 50 mg) oral, or non-sedating second-generation antihistamine 2, 3
• H2 antihistamine: Ranitidine twice daily may be added 2
• Monitor closely for 30-60 minutes to ensure no progression to anaphylaxis 2
• If symptoms worsen or systemic signs develop, administer epinephrine immediately 2, 3

Discharge Management

After stabilization of acute reaction:

Medications for 2-3 days:

• H1 antihistamine: Diphenhydramine every 6 hours OR non-sedating second-generation antihistamine 2
• H2 antihistamine: Ranitidine twice daily 2
• Corticosteroid: Prednisone daily (for moderate-severe reactions) 2

Patient education:

• Permanent avoidance of cyclobenzaprine and structurally similar tricyclic compounds 1
• Provide written documentation of allergy for medical records 1
• If anaphylaxis occurred: prescribe epinephrine auto-injector (2 doses) with training 2, 3
• Consider medical alert bracelet/card 2

Follow-up:

• Primary care physician within days 2
• Allergist-immunologist referral for confirmed drug allergy 2, 3

Critical Considerations

Cyclobenzaprine-specific risks:

• Structurally related to tricyclic antidepressants (amitriptyline), so cross-reactivity possible 4
• Recent pharmacovigilance data shows drug hypersensitivity as a significant adverse event signal 5
• The FDA label explicitly warns to discontinue if hypersensitivity suspected 1

Common pitfall: Do not confuse withdrawal symptoms (malaise, nausea, headache lasting 2-4 days after discontinuation) with allergic reactions 4. Withdrawal is uncomfortable but not life-threatening and does not require epinephrine.

Alternative muscle relaxants: Consider switching to agents with unrelated chemical structures such as methocarbamol, metaxalone, or tizanidine 4, though individual allergy assessment is needed.

Never rechallenge: Unlike some drug reactions where graded challenge or desensitization may be considered, the FDA contraindication for cyclobenzaprine hypersensitivity is absolute 1. There are acceptable alternative muscle relaxants available, making rechallenge unnecessary and inappropriate.